Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 18601-18610

  Basyigit, Sebahat ^a   Uzman, Metin ^a   Kefeli, Ayse ^b   Sapmaz, Ferdane Pirincci ^a   Yeniova, Abdullah Ozgür ^c   Nazligul, Yasar ^a   Asiltürk, Zeliha ^a  

^a Kecioren Teaching and Research Hospital   (Turkey)

^b SIIRT STATE HOSPITAL   (Turkey)

^c Gaziosmanpasa Universtiy   (Turkey)

Author keywords

Cancer pathogenesis; Colonoscopy; Colorectal neoplasm screening; Hepatosteatosis; Insulin resistance

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CANCER RISK; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PROSPECTIVE STUDY;

EID: 84949634791     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 Inciden-ce and Mortality Website Report. Published 2009.
2. Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003; 228: 396-405.
3. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994; 3: 687-95.
4. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995; 122: 327-34.
5. Lu K, Song XL, Han SL Wang CH, Zhong N, Qi LF. Potential Study Perspectives on Me-chanisms and Correlations Between Adiposity and Malignancy. Asian Pac J Cancer Prev 2014; 15: 1057-60.
6. La Brecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JFR, Sarin S, Stimac D, Thomson ABR, Umar M, Krabshuis J, LeMair A. World Gastroenterology Organisation Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steato-hepatitis. J Clin Gastroenterol 2014; 48: 467-73.
7. Forootan M, Tabatabaeefar M, Yahyaei M, Maghsoodi N. Metabolic Syndrome and Colo-rectal Cancer: A Cross-Sectional Survey. Asian Pacifc J Cancer Prev 2012; 13: 4999.
8. Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jin W. Relationship of non alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010; 25: 562-7.
9. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-36.
10. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non alcoholic fatty liver disease in Korean women: A retrospective cohort study. J Gastroenterol Hepatol 2012; 27: 91-5.
11. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, Zannad F. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925-38.
12. WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia Pty Ltd, 2000.
13. American Diabetes Association (ADA). Clinical practice recommendations. Diabetes Care 2007; 30 Suppl 1: S42-7.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-9.
16. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-61.
17. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013-5.
18. Corpet DE, Jacquinet C, Peiffer G, Tache S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr Cancer 1997; 27: 316-20.
19. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91: 1147-54.
20. Kaaks R, TonioloP, Akhmedkhanov A. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins,and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-600.
21. Yang YX, Hennessy S, Lewis JD. Noninsulin dependent diabetes mellitus and colorectal cancer risk. Gastroenterology 2003; 124: A547.
22. Hsing AW, Gao YT, Chua S, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 67-71.
23. Rose DP, Komninou D, Stephenson GD. Obe-sity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004; 5: 153-165.
24. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-8.
25. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80.
26. Remacle-Bonnet MM, Culouscou JM, Garrouste FL, Rabenandrasana C, Marvaldi JL, Pommier GJ. Expression of type 1, but not type 2 insulin-like growth factor (IGF) receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell lines. J Clin Endocr Metab 1992; 75: 609-16.
27. Karimi K, Mahmoudi T, Karimi N, Dolatmo-radi H, Arkani M, Farahani H, Vahedi M, Parsimehr E, Dabiri R, Nobakht H, Asadi A, Zali MR. Is there an Association between Variants in Candidate Insulin Pathway Genes IGF-I, IGFBP-3, INSR, and IRS2 and Risk of Colorectal Cancer in the Iranian Population? Asian Pac J Cancer Prev 2013; 14: 5011-6.
28. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. “Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy,” Proc Natl Acad Sci U S A 1991; 24: 11555-8.
29. Giardino I, Edelstein D, Brownlee M. Non-enzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 1: 110-7.
30. Moller DE and Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48.
31. Sims MA, Hasler WL, Chey WD, Kim MS, Ow-yang C. Hyperglycemia inhibits mechanoreceptor-mediated gastrocolonic responses, and colonic peristaltic reflexes in healthy humans. Gastroenterology 1995; 108: 350-9.
32. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996; 271: 665-8.
33. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
34. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-7.
35. Vakkila J and Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648.
36. Zheng L, Dai H, Zhouet M. Fen 1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med 2007; 13: 812-9.
37. Stadlmayr A, Aigner E, Stegeretal B. Nonal-coholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Inter Med 2011; 270: 41-49.
38. Touzin NT, Bush KN, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Ther Adv Gastroenterol 2011; 4: 169-76.
39. Lambert MS, Avella MA, Berhane Y, Shervill E, and Botham KM. The fatty acid composition of chylomicron remnants influences their binding and internalization by isolated hepatocytes. Eur J Biochem 2001; 268: 3983-92.
40. Bradbury MW. Lipid Metabolism and Liver Inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G194-G198.
41. Mc Namara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enteral Nutr 1992; 16 Suppl: 50S-55S.
42. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-80.
43. Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C. Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Athero-sclerosis 1999; 142: 379-387.
44. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Meta Rev 2006; 25: 387-408.
45. Kreger BE, Anderson KM, Schatzkin A, Splan-sky GL. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framing-ham Study. Cancer 1992; 70: 1038-43.
46. Kitahara CM, de González AB, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011; 29: 1592-8.
47. Keneko R, Nakazaki N, Tagawa T, Ohishi C, Kusayanagi S, Kim M, Baba T, Ogawa M, Sato Y. A New Index of Abdominal Obesity which Effectively Predicts Risk of Colon Tumor Development in Female Japanese. Asian Pac J Cancer Prev 2014; 15: 1005-10.
48. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumi-trascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastro-enterol 2009; 15: 5141-8.
49. Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eyssen G, Bruce WR, Giacca A. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endo-crinology 2006; 147: 1830-7.
50. Scatarige JC, Scott WW, Donovan PJ, Siegelman SS, Sanders RC. Fatty infiltration of the ultrasonographic and computed tomographic correlation. J Ultrasound Med 1984; 3: 9-14.